SQLite Web: event_store.db

Update row 46926 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-15T02:18:53.247056+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:7521d16711d9e3e8","evidence_event_ids":["evt_747281d6aa6d"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-043571.txt","as_of":"2026-04-15T02:18:53.247056+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-043571.txt","company":"Silo Pharma, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-043571.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_57db20a819fb4d0c","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-043571.txt","content_type":"text/plain","enriched_at":"2026-04-15T07:18:55.827794+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-043571.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-043571.txt","source_event_id":"evt_747281d6aa6d","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"POS AM","fp":"c08544b9ccdbc49d","kind":"sec_filing","published_at":"20260414","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-14","2026-04-15T02:18:53.247056+00:00","2026-03-27","2025-05-15","2025-12-31"],"entities":[{"asset_class":"equity","name":"Silo Pharma, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"regulation","name":"Securities and Exchange Commission","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"management","name":"Eric Weisblum","relevance":"low","symbol":"","type":"person"}],"event_type":"listing","information_gaps":["What specific sections or disclosures from the FY 2025 Form 10-K were incorporated is not detailed in the provided text.","The text does not specify any changes to offering terms beyond stating the update and that no additional securities are registered.","The provided excerpt does not include the full prospectus details (e.g., risk factors, use of proceeds, or updated financial figures).","No prior-known-state details (e.g., what was previously missing/changed) are provided beyond the general statement that this amendment updates/supplements information."],"key_facts":["The filing is titled \u201cAmendment No. 1 to Form S-1 Registration Statement\u201d and is a \u201cPost-Effective Amendment No. 1.\u201d","It states it is filed pursuant to undertakings in the Original Registration Statement to update and supplement information.","The Original Registration Statement was declared effective on May 15, 2025.","The Original Registration Statement (and this amendment) pertains solely to registration of: 2,416,670 Series A-1 Warrants, 2,356,670 Series A-2 Warrants, Placement Agent Warrants to purchase up to 250,000 shares of common stock, and up to 5,023,340 shares of common stock underlying the common stock purchase warrants and placement agent warrants.","The amendment incorporates certain information from Silo Pharma\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, filed March 27, 2026.","The amendment states that no additional securities are being registered under this Post-Effective Amendment No. 1.","The filing states all applicable registration fees were previously paid."],"numeric_claims":[{"label":"Series A-1 Warrants","value":"2,416,670"},{"label":"Series A-2 Warrants","value":"2,356,670"},{"label":"Placement Agent Warrants (shares purchasable)","value":"up to 250,000"},{"label":"Common stock underlying warrants (shares)","value":"up to 5,023,340"},{"label":"Original S-1 effective date","value":"May 15, 2025"},{"label":"10-K filing date incorporated","value":"March 27, 2026"},{"label":"Post-Effective Amendment filing date (stated)","value":"April 14, 2026"}],"primary_claim":"Post-Effective Amendment No. 1 to Silo Pharma, Inc.\u2019s Form S-1 was filed on April 14, 2026 to update the registration statement using information from the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, and it registers no additional securities.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Silo Pharma, Inc. filed Post-Effective Amendment No. 1 to its Form S-1 (Registration No. 333-286777) on April 14, 2026. The amendment updates the registration statement by incorporating information from the company\u2019s FY 2025 Form 10-K and does not register any additional securities.","topics":["SEC filing","Form S-1","post-effective amendment","warrants","registration statement update","Form 10-K incorporation"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form POS AM \u00b7 Silo Pharma, Inc. \u00b7 Filed 20260414","ticker":"SILO","tickers":["SILO"],"title":"SILO filed POS AM","url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-043571.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel